| Outcome Measures: |
Primary: Central (aortic) pulse pressure assessed by Sphygmocor XCEL, The primary objective of the study is to analyze the effect of semaglutide, compared to placebo, on: central (aortic) pulse pressure after 16 weeks of treatment from baseline, 16 weeks | Secondary: Central (aortic) systolic pressure assessed by Sphygmocor XCEL, change of central (aortic) systolic pressure after 16 weeks of treatment from baseline, 16 weeks|Augmentation pressure assessed by Sphygmocor XCEL, change of augmentation pressure after 16 weeks of treatment from baseline, 16 weeks|Augmentation index (cAIX@75) assessed by Sphygmocor XCEL, change of augmentation index (cAIX@75) after 16 weeks of treatment from baseline, 16 weeks|Forward wave amplitude assessed by Sphygmocor XCEL, change of forward wave amplitude after 16 weeks of treatment from baseline, 16 weeks|Backward wave amplitude assessed by Sphygmocor XCEL, change of backward wave amplitude after 16 weeks of treatment from baseline, 16 weeks|Outer diameter of small retinal arterioles assessed by Scanning laser Doppler flowmetry, change of outer diameter of small retinal arterioles after 16 weeks of treatment from baseline, 16 weeks|Inner diameter of small retinal arterioles assessed by Scanning laser Doppler flowmetry, change of inner diameter of small retinal arterioles after 16 weeks of treatment from baseline, 16 weeks|Wall to lumen ratio of small retinal arterioles assessed by Scanning laser Doppler flowmetry, change of wall to lumen ratio of small retinal arterioles after 16 weeks of treatment from baseline, 16 weeks|Flow-mediated Vasodilation (FMD) of the brachial artery assessed by UNEX EF, change of FMD of the brachial artery after 16 weeks of treatment from baseline, 16 weeks|Pulse wave velocity assessed by Sphygmocor XCEL, change of pulse wave velocity after 16 weeks of treatment from baseline, 16 weeks|24-h ambulatory BP (brachial and central) assessed by Mobil-O-Graph®, change of 24-h ambulatory BP (brachial and central) after 16 weeks of treatment from baseline, 16 weeks|24-h ambulatory vascular parameter assessed by Mobil-O-Graph®, change of 24-h ambulatory vascular parameter (pulse wave velocity) from baseline, 16 weeks|24-h ambulatory vascular parameter assessed by Mobil-O-Graph®, change of 24-h ambulatory vascular parameter (central pulse pressure, central systolic pressure) from baseline, 16 weeks|Renal perfusion of both kidneys assessed by Arterial Spin Labeling MRI, change of renal perfusion (total, cortical, medullary) from baseline, 16 weeks
|
